Article Text
Therapeutics/Prevention
Randomised controlled trial
Liraglutide, a GLP-1 receptor agonist, prevents cardiovascular outcomes in patients with type 2 diabetes
Statistics from Altmetric.com
Footnotes
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.